<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_UT_Dallas_immunobot_intro"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:UT_Dallas/immunobot_intro">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:UT_Dallas/immunobot_intro&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:UT_Dallas/immunobot_intro&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:UT_Dallas/immunobot_intro&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:UT_Dallas/immunobot_intro" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:UT Dallas/immunobot intro</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2011.igem.org</H3><DIV class="container"><DIV id="header"><DIV id="crumbs"><A target="_blank" href="http://www.utdallas.edu/" style="color: #FFFFFF;float: left;text-decoration: none;">The University of Texas at Dallas</A><A target="_blank" href="https://2010.igem.org/Team:UTDallas" style="color: #FFFFFF;float: right;text-decoration: none;">2010 iGEM UTD Wiki</A></DIV></DIV><DIV class="contents"><DIV id="container2"><DIV id="container1"><DIV id="left"><UL id="accmenu"><LI><A class="head" href="#">Overview</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas">Home</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/team">About Us </A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/gallery">Gallery</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/biobricks">BioBricks </A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/Acknowledgments">Acknowledgments</A></LI></UL><LI><A class="head" href="#">Immunobots</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/immunobot_intro">Introduction</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/immunobot_anim">Animation</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/immunobot_modeling">Modeling</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/immunobot_results">Results</A></LI><LI><A class="head" href="#">Killbots</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/killbots_intro">Introduction</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/killswitch_results">Results</A></LI><LI><A class="head" href="#">Human Practices</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/considerations">Considerations</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/safety">Safety</A></LI><LI><A class="head" href="#">Notebook</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/protocols_new">Protocols</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/notebook_dates">Calendar</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/dna_ladder">DNA Ladders</A></LI><LI><A class="head" href="#">Android Apps</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/ligation">Ligation Calculator</A></LI><LI><A href="https://2011.igem.org/Team:UT_Dallas/NEB_double_digest">NEB Double Digest</A></LI><LI><A class="head" href="https://2011.igem.org/Team:UT_Dallas/data" onclick="window.location='https://2011.igem.org/Team:UT_Dallas/data';return false">Data</A></LI></DIV><DIV id="right"><H2>Introduction</H2>
Inflammatory bowel disease (IBD) is a group of increasingly prevalent disorders that afflicts
parts of the human gastrointestinal tract and results in significant tissue damage. IBD manifests
primarily as Crohn’s disease and ulcerative colitis. These disorders both have ambiguous
disease etiology, which complicates a timely diagnosis. Generally considered autoimmune
disorders, treatment often involves anti-inflammatory and immunosuppressive medications
and surgical intervention. However, these have temporary success and mainly work to alleviate
symptoms and maintain remission. Thus, IBD remains without a cure.

Wound healing involves a complex series of biochemical events that progress in distinct stages:
inflammation, proliferation and remodeling. Tissue repair takes place during the proliferative
and remodeling stages during which a balance of collagen production and degradation is
maintained. However, repair of IBD-damaged tissue is particularly difficult since these are
chronic wounds locked in a prolonged inflammatory state that can result in further damage as
collagen degradation overwhelms production. In 2009, Stanford developed a two-component
probiotic that regulates the activity of lymphocytes involved in inflammation. To build on their
work, we developed a means to localize tissue repair following control of inflammation. As a
human gut symbiont, we selected an E. coli chassis for its well-characterized machinery and the
vast supply of E.coli-compatible tools available in the Registry.

&quot;Immunobots&quot; are composite sensor-taxis devices that interpret wound signals to identify
tissue damage and migrate towards damage sites, such as those resulting from IBD.
Immunobots can work with another device that facilitates tissue repair, which takes an
important step towards achieving a more durable treatment for IBD.
<B>References:</B>
Baumgart, Daniel C C. et. al. (2007). Inflammatory bowel disease: clinical aspects and
established and evolving therapies. The Lancet. 369(9573): 1641-57 (doi:10.1016/S0140-
6736(07)60751-X)

Midwood, K.S. et. al. (2004). Tissue repair and the dynamics of the extracellular matrix.
The International Journal of Biochemistry &amp; Cell Biology. 36 (6): 1031–1037. (doi:10.1016/
j.biocel.2003.12.003)

Stanford iGEM 2009 (<A href="https://2009.igem.org/Team:Stanford/" target="_blank">https://2009.igem.org/Team:Stanford/</A>)
<B>Sensing Module</B>
Fibroblasts play a critical role in the proliferative stage of wound healing. Fibroblast growth
factors (FGFs) promote increased fibroblast cell differentiation and proliferation. Therefore
FGFs can represent wound signals for our immunobot sensing module. FGFs work with Heparin
sulfate-containing proteoglycans to induce the FGF receptor (FGFR). Once induced, FGFR
dimerizes and triggers FGF signal transduction.

We wished to connect wound signaling inputs to movement in order to achieve localization at
the site of tissue damage. This requires an intermediate that would link FGFR to chemotaxis,
since the systems do not naturally share common machinery. Kolmar et. al. achieved a similar
effect in E. Coli. Their system included a chimeric receptor consisting of a maltose-inducible
component and ToxR transcription factor. Activated ToxR forms a homodimer that induces the
CTX promoter. They cloned CTX upstream of bacterial chemotaxis genes that produce straight-
line movement to achieve maltose-induced chemotaxis.

The dimerization properties of ToxR receptor made it particularly attractive for use in our
system. Thus, we produced a chimeric receptor that includes a FGFR-ToxR fusion, which is
to our knowledge, the first of its kind in the Registry. The activated complex induces CTX-
controlled chemotaxis, hence completing the linkage between wound signals and movement.
<B>Taxis Module</B>
Bacterial chemotaxis in our chassis (E. coli DH5a) involves interactions of transmembrane
receptor proteins known as methyl accepting chemotactic proteins (MCP). Each MCP within the
cell uses the same intracellular signals to control movement towards different chemicals. These
signals include the six Che proteins: CheA, CheB, CheR, CheW, CheY and CheZ.

Chemotaxis involves systematic interactions among the Che proteins to produce movement
along gradients of inducers. Initially, a ligand binds to the extracellular portion of MCP, which
and induces a three dimensional conformational change that extends throughout the cell. Once
this happens, CheA also undergoes a conformational change leading to an increase in activity by
autophosphorylation. At this point, CheY interacts with the activated phosphorylated CheA via
diffusion and becomes phosphorylated itself by the newly activated CheA. CheY then forms a
complex with the flagellar motor proteins (FLiM) and induces clockwise rotations
of the flagella. This causes the cell to tumble in place with no net movement. Alternatively,
CheZ, another chemotactic regulator protein, dephosphorylates CheY. This decreases the
cellular concentration of CheY, so less phosphorylated CheY binds the FLiM protein. As a
result, the flagella instead rotate counter clockwise, inducing straight line movement as the
cell runs along gradients. CheW and CheR respectively methylate and demethylate the MCP
receptor. The opposing actions of methylating and demethylating prevent double counting the
chemical signals. These events are summarized in this <A target="_blank" href="http://highered.mcgraw-
hill.com/olcweb/cgi/pluginpop.cgi?it=swf::500::500::/sites/dl/free/0073375225/594355/
Chemotaxis.swf::Chemotaxis%20in%20E.%20Coli">video</A>.

We wished to produce runs along wound signal gradients to demonstrate chemotactic activity
toward tissue damage sites. This requires overexpressing CheZ, which will keep cellular
concentrations of CheY low and favor straight line movement over tumbling. To achieve this,
we fused the CTX promoter with CheZ. In addition, Silversmith et. al. reported a hyperactive
mutant form of CheZ protein, CheZ*, which we also fused with the CTX promoter to further
increase dephosphorylation of CheY. Wound signals will thus activate dimerization of our
chimeric receptor, which then induces the CTX-controlled CheZ and CheZ* constructs producing
straight line movement along wound signal gradients.
<B>References</B>
Plotnikov, A. et. al. (1999). Structural Basis for FGF Receptor Dimerization and Activation Cell.
Cell. 98: 641–650.

Ornitz, D.M. et. al. (2001). Fibroblast growth factors. Genome Biol. 2 (3): Reviews 3005.
(doi:10.1186/gb-2001-2-3-reviews3005)

Kolmar et. al. (1994). Dimerization of Bence Jones Proteins: Linking the Rate of Transcription
from an Escherichia coli Promoter to the Association Constant of REIv. Biol. Chem. Hoppe-
Seyler. 375: 61-70.

Silversmith, R et. al. (2007). Kinetic Characterization of Catalysis by the Chemotaxis
Phosphatase CheZ: Modulation of Activity by the Phosphorylated CheY Substrate. Journal of
Biological Chemistry. 283 (2): 756-65.</DIV></DIV></DIV></DIV></DIV></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2011.igem.org/Team:UT_Dallas/immunobot_intro">http://2011.igem.org/Team:UT_Dallas/immunobot_intro</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:UT_Dallas/immunobot_intro" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:UT_Dallas/immunobot_intro" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:UT_Dallas/immunobot_intro&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:UT_Dallas/immunobot_intro&amp;oldid=198772" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2011.igem.org:Privacy_policy" title="2011.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2011.igem.org:General_disclaimer" title="2011.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></BODY></HTML>